Cellprint Biotechnology LLC

Copernicus Therapeutics is a privately held company developing products for human gene therapy and vaccination. Copernicus was established in 1997 based on technologies discovered at Case Western Reserve University that provide the foundation for the use of DNA as drugs. The company focuses on using its technologies to make and sell gene therapy products to treat, cure or prevent human diseases. It intends to become a leading biopharmaceutical company by utilizing its DNA nanoparticle technologies to produce safe and effective DNA drugs. To maximize shareholder value, the company is using its expertise in lung gene transfer by developing products for the cystic fibrosis market. Its second therapeutic product will be for treating hemophilia B. Copernicus Therapeutics is headquartered in Cleveland.

Neoproteomics Inc is a Cleveland-based company specializing in advanced proteomics research and development. With a focus on Japan, they offer a range of innovative solutions and technologies for protein analysis, including the identification and characterization of proteins, protein-protein interactions, and post-translational modifications. Utilizing cutting-edge techniques and state-of-the-art equipment, Neoproteomics Inc provides comprehensive proteomic services to academic institutions, pharmaceutical companies, and biotechnology firms. Their expertise in proteomics enables them to contribute to advancements in drug discovery, personalized medicine, and biomarker identification, making them a trusted partner in the field of proteomics research.Generated from the website

Cell X Technologies, Inc, located in Cleveland, OH, is at the forefront of the cell processing revolution with its transformative Celligent™ platform. This innovative combination of robotics, imaging, and artificial intelligence empowers developers to create consistent, reproducible, and scalable GMP-compliant processes for cellular therapies, tissue engineering, and artificial organ applications. By harnessing cutting-edge technologies, Cell X unlocks the potential of imaging, data analysis, and machine learning to gain unprecedented insights into cell culture processes. The Celligent platform facilitates early identification of critical quality attributes, determination of replicable process parameters, and optimization of production steps through ongoing refinements driven by artificial intelligence. With a strong emphasis on automation and machine learning, Cell X ensures a comprehensive suite of features from sample preparation to cell culturing. This commitment to precise and reproducible results enhances safety, efficacy, and regulatory compliance, ultimately making advanced cell therapies more accessible to a global audience. Generated from the website content